Celgene Corporation - Product Pipeline Review - 2016

  • ID: 3691102
  • Company Profile
  • 173 pages
  • Global Markets Direct
  • Celgene Corporation
1 of 4
Celgene Corporation - Product Pipeline Review - 2016

Summary

‘Celgene Corporation - Product Pipeline Review - 2016’, provides an overview of the Celgene Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Celgene Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Celgene Corporation
- The report provides overview of Celgene Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Celgene Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Celgene Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Celgene Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Celgene Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Celgene Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Celgene Corporation Snapshot

Celgene Corporation Overview

Key Information

Key Facts

Celgene Corporation - Research and Development Overview

Key Therapeutic Areas

Celgene Corporation - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Celgene Corporation - Pipeline Products Glance

Celgene Corporation - Late Stage Pipeline Products

Celgene Corporation - Clinical Stage Pipeline Products

Celgene Corporation - Early Stage Pipeline Products

Celgene Corporation - Drug Profiles

apremilast

lenalidomide

azacitidine

CC-90007

mongersen

paclitaxel albumin bound

pomalidomide

romidepsin

amrubicin hydrochloride

CC-11050

CC-220

GI-6207

GI-6301

PDA-002

spebrutinib besylate

Stem Cell Therapy for Hematological Malignancies, Non-Malignant Disorders and Hypoxic-ischemic Encephalopathy

CC-122

CC-223

PNK-007

CC-115

CC-90001

CC-90002

CC-90003

CC-90005

Cellular Immunotherapy to Target GD2 for Neuroblastoma

CTP-730

pinometostat

AVL-181

AVL-192

CC-0730671

CC-2142

CC-509

CC-539

Monoclonal Antibody 1 for Inflammation

Monoclonal Antibody 2 for Inflammation

Small Molecules for Undisclosed Indication

Small Molecules to Agonize ROR gamma for Breast Cancer

Antibody for Oncology

Antibody for Undisclosed Indication

CC-0739623

CC-2141

CC-90006

CC-90008

CC-90009

CC-90010

CC-90011

CSC-1

Drug for Hematological Disorders and Oncology

Drug to Inhibit Kinase for Inflammation

Drugs for Hematology and Oncology

Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS

Small Molecule to Inhibit Brutons Tyrosine Kinase for Inflammation

Small Molecules for Inflammation

Small Molecules for Inflammation and Cancer

Small Molecules for Malaria

Celgene Corporation - Pipeline Analysis

Celgene Corporation - Pipeline Products by Target

Celgene Corporation - Pipeline Products by Route of Administration

Celgene Corporation - Pipeline Products by Molecule Type

Celgene Corporation - Pipeline Products by Mechanism of Action

Celgene Corporation - Recent Pipeline Updates

Celgene Corporation - Dormant Projects

Celgene Corporation - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Celgene Corporation - Company Statement

Celgene Corporation - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Celgene Corporation, Key Information

Celgene Corporation, Key Facts

Celgene Corporation - Pipeline by Indication, 2016

Celgene Corporation - Pipeline by Stage of Development, 2016

Celgene Corporation - Monotherapy Products in Pipeline, 2016

Celgene Corporation - Partnered Products in Pipeline, 2016

Celgene Corporation - Partnered Products/ Combination Treatment Modalities, 2016

Celgene Corporation - Out-Licensed Products in Pipeline, 2016

Celgene Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016

Celgene Corporation - Pre-Registration, 2016

Celgene Corporation - Phase III, 2016

Celgene Corporation - Phase II, 2016

Celgene Corporation - Phase I, 2016

Celgene Corporation - Preclinical, 2016

Celgene Corporation - Discovery, 2016

Celgene Corporation - Pipeline by Target, 2016

Celgene Corporation - Pipeline by Route of Administration, 2016

Celgene Corporation - Pipeline by Molecule Type, 2016

Celgene Corporation - Pipeline Products by Mechanism of Action, 2016

Celgene Corporation - Recent Pipeline Updates, 2016

Celgene Corporation - Dormant Developmental Projects,2016

Celgene Corporation - Discontinued Pipeline Products, 2016

Celgene Corporation, Other Locations

Celgene Corporation, Subsidiaries

List of Figures

Celgene Corporation - Pipeline by Top 10 Indication, 2016

Celgene Corporation - Pipeline by Stage of Development, 2016

Celgene Corporation - Monotherapy Products in Pipeline, 2016

Celgene Corporation - Partnered Products in Pipeline, 2016

Celgene Corporation - Out-Licensed Products in Pipeline, 2016

Celgene Corporation - Pipeline by Top 10 Target, 2016

Celgene Corporation - Pipeline by Route of Administration, 2016

Celgene Corporation - Pipeline by Molecule Type, 2016

Celgene Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll